Although the synergistic efficacy between CpG and shRNAStat3 for in vivo T cell responses or tumor immunotherapy has yet to be investigated, the potent T cell responses and tumor therapeutic efficacy of iDR-NC/Adpgk are presumably attributed, at least in part, to this synergistic APC activation. This evidence concerns the gene APC and neoplasm.